Australia markets open in 2 hours 7 minutes

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.61-2.44 (-20.21%)
As of 03:53PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 939.44M
Enterprise value 790.28M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)4.89
Enterprise value/revenue N/A
Enterprise value/EBITDA -15.50

Trading information

Stock price history

Beta (5Y monthly) 0.71
52-week change 3-33.02%
S&P500 52-week change 3-11.32%
52-week high 320.24
52-week low 37.13
50-day moving average 311.36
200-day moving average 310.58

Share statistics

Avg vol (3-month) 31.76M
Avg vol (10-day) 36.32M
Shares outstanding 577.96M
Implied shares outstanding 6N/A
Float 875.61M
% held by insiders 13.02%
% held by institutions 132.13%
Shares short (14 Nov 2022) 410.17M
Short ratio (14 Nov 2022) 410.28
Short % of float (14 Nov 2022) 413.42%
Short % of shares outstanding (14 Nov 2022) 413.04%
Shares short (prior month 13 Oct 2022) 410.04M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 306 Oct 2015

Financial highlights

Fiscal year

Fiscal year ends 29 Sept 2022
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-18.95%
Return on equity (ttm)-32.71%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-47.98M
Diluted EPS (ttm)-0.58
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)149.16M
Total cash per share (mrq)1.91
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)14.95
Book value per share (mrq)1.83

Cash flow statement

Operating cash flow (ttm)-24.24M
Levered free cash flow (ttm)-6.03M